Article Details

AstraZeneca secures China approval for treating mild asthma with Symbicort Turbuhaler

Retrieved on: 2021-01-27 08:37:30

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca secures China approval for treating mild asthma with Symbicort Turbuhaler. View article details on HISWAI: https://www.pharmaceutical-business-review.com/news/astrazeneca-china-approval-mild-asthma-symbicort-turbuhaler/

Excerpt

Astrazeneca's Symbicort approved for treating mild asthma. (Credit: AstraZeneca.) Subscribe to our email newsletter. The approval for Symbicort ...

Article found on: www.pharmaceutical-business-review.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up